Luminex Resources Corp (LR) News

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Aries to clinically develop and market Enveric’s patented product for radiation dermatitis Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a...

Form 8-K - Current report

Enveric Biosciences Announces Patent Granted for Drug Candidate

US patent includes broad claims for treating brain neurological disorders Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a...

Form S-3 - Registration statement under Securities Act of 1933

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically...

Form 3 - Initial statement of beneficial ownership of securities

Enveric Biosciences to Participate in BIO International Convention 2024

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial...

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact...

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Biotechnology licensee expected to progress methods targeting breast and other cancers using cannabinoids in combination with chemotherapeutic...

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing...